Pasithea Therapeutics Corp. (KTTA) - 2024 Form 10-K Summary
Business Context and Reporting Period
Company: Pasithea Therapeutics Corp.
Reporting Period: Fiscal year ended December 31, 2024.
Business Model: Clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders and RASopathies. The company operates as a single reportable segment ("Therapeutics").
Key Developments:
- Discontinued support services for anti-depression clinics (Clinics segment) and clinical operations in Los Angeles in 2023; these are now classified as discontinued operations.
- Completed a 1:20 reverse stock split effective January 2, 2024.
- Advanced lead candidate PAS-004 (MEK inhibitor) into a First-in-Human (FIH) Phase 1 Dose Escalation Study.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.9) million | $(16.0) million |
| Operating Expenses | $(14.2) million | $(16.0) million |
| Research & Development (R&D) | $(7.2) million | $(8.1) million |
| Selling, General & Administrative (SG&A) | $(7.1) million | $(7.9) million |
| Cash and Cash Equivalents (Year End) | $6.9 million | $16.3 million |
| Working Capital | $6.2 million | $14.1 million |
| Accumulated Deficit | $(49.6) million | $(35.3) million |
Note: The company has no revenue and is not profitable. Margins are not applicable.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $2.1 million (12.9%) compared to 2023, primarily due to reduced operating expenses.
- Expense Management:
- SG&A: Decreased by $0.8 million (10.5%) driven by lower professional fees (public company communications, business development) and legal fees.
- R&D: Decreased by $0.9 million (11.1%). This was due to a $2.0 million decrease in pre-clinical research and a $1.1 million decrease in manufacturing costs (bulk manufacturing occurred in 2023). These savings were partially offset by a $2.6 million increase in clinical research costs for the ongoing FIH Phase 1 study.
- Liquidity: Cash and cash equivalents decreased by $9.4 million, reflecting cash used to fund operations, partially offset by $4.5 million in net proceeds from a private placement in September 2024.
- Discontinued Operations: The 2023 net loss included $0.45 million from discontinued operations (Clinics segment), which was not present in 2024.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Capital Needs: Management states that as of December 31, 2024, the company does not have sufficient working capital to meet its needs for the next twelve months without raising additional capital. An "At The Market" (ATM) offering agreement was established in November 2024, and a private placement in September 2024 raised approximately $4.5 million.
- Clinical Timeline: The FIH Phase 1 Dose Escalation Study for PAS-004 is expected to be completed in 2026. A Phase 1/1b clinical trial in adult NF1-PN patients is planned to initiate in the first half of 2025.
- Expense Trend: R&D expenses are expected to increase in 2025 due to clinical research for PAS-004 and manufacturing costs, while SG&A is expected to decrease slightly.
Risks and Contingencies:
- Going Concern: The independent auditor has issued an explanatory paragraph regarding "Going Concern," citing significant losses and the need for additional funding to sustain operations.
- Third-Party Dependence: The company relies entirely on third-party contract manufacturing organizations (CMOs), specifically WuXi AppTec (China-based), for drug substance and product. Risks include potential supply chain disruptions, geopolitical tensions, and U.S. legislative proposals (e.g., BIOSECURE Act) targeting Chinese biotechnology companies.
- Regulatory Approval: No products are approved. Success depends on the safety and efficacy of PAS-004, which is still in Phase 1 trials.
- Intellectual Property: The company relies on patents for PAS-004 (expiring 2030-2045) and PAS-003 (expiring 2042-2043).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.9 million cash balance against the projected burn rate for 2025, given the explicit statement that funds are insufficient for 12 months without new capital.
- Financing Activity: Monitor the utilization of the ATM agreement and any new equity/debt offerings to fund the upcoming Phase 1/1b trial in 2025.
- Clinical Data: Review interim data releases from the PAS-004 FIH Phase 1 study (specifically safety, tolerability, and pharmacokinetics) expected throughout 2025.
- Supply Chain Risk: Assess the impact of potential U.S. legislation (BIOSECURE Act) on the company's reliance on WuXi AppTec for manufacturing.
- Warrant Liabilities: Monitor the fair value adjustments of warrant liabilities, which impacted "Other income/expense" in the current period.